MedPath

Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis

Not Applicable
Recruiting
Conditions
Multiple Sclerosis, Relapsing-Remitting
Optic Neuritis
Interventions
Device: Light stimulation
Device: Sham light stimulation
Registration Number
NCT06389968
Lead Sponsor
Technical University of Munich
Brief Summary

The aim of this monocentric randomized controlled intervention study is to improve visual function in persons with multiple sclerosis following optic neuritis (neuritis nervi optici) by means of a light stimulation.

In the treatment arm, two 80-second light stimulations are to be administered daily for 12 days in 25 persons with multiple sclerosis following recent optic neuritis (1-3 months). For the standardized application of light stimulation in the sense of standardized training, the light stimulation is to be carried out by watching a generated flicker video on a mobile phone. In a sham-intervened control group (sample size 25), the spontaneous course after optic neuritis will be recorded in parallel. Intensive neuronal stimulation of the visual pathway will be used to stimulate regenerative processes, which will be recorded by means of changes in high-contrast visual acuity (primary endpoint). Secondary endpoints are changes in a colored-contrast test, in 2.5% low contrast visual acuity, the peak conduction latency of visual evoked potentials, and retinal layer thicknesses and vessel densities measured in optical coherence tomography and optical coherence tomorgraphic angiography. These physiological parameters should help to understand the underlying processes of a potentially altered visual performance.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Relapsing remitting multiple sclerosis or clinically isolated syndrome or no indication of chronic inflammatory central nervous system disease
  • Age 18-60 years
  • Optic neuritis within 1-3 months
Exclusion Criteria
  • Epilepsy
  • Light-triggered migraine
  • Insufficient vision correction
  • Retinal disease (glaucoma, macular edema, macula degeneration, ...)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Light stimulationLight stimulationExperimental light stimulation (3 colors at 20 Hertz each for 80 seconds twice a day).
Sham light stimulationSham light stimulationSham light stimulation (white screen for 80 seconds twice a day).
Primary Outcome Measures
NameTimeMethod
High contrast visual sensitivitybefore intervention, directly after the first stimulation, after 12 days of training (stimulation) as 24 hour retention, and at 22 days post-intervention (retention)

Visual resolution with Sloan chart

Secondary Outcome Measures
NameTimeMethod
Low contrast visual sensitivitybefore intervention, directly after the first stimulation, after 12 days of training (stimulation) as 24 hour retention, and at 22 days post-intervention (retention)

Sloan chart at 2.5%

Optical coherence tomographybefore intervention, directly after the first stimulation, after 12 days of training (stimulation) as 24 hour retention, and at 22 days post-intervention (retention)

Optical coherence tomography

Optical coherence tomographic angiographybefore intervention, directly after the first stimulation, after 12 days of training (stimulation) as 24 hour retention, and at 22 days post-intervention (retention)

Optical coherence tomographic angiography

Visually evoked potentialsbefore intervention, directly after the first stimulation, after 12 days of training (stimulation) as 24 hour retention, and at 22 days post-intervention (retention)

Visually evoked potential

Color contrastbefore intervention, directly after the first stimulation, after 12 days of training (stimulation) as 24 hour retention, and at 22 days post-intervention (retention)

Color contrast threshold (3 colors)

Trial Locations

Locations (1)

Technical University of Munich

🇩🇪

Munich, Bavaria, Germany

© Copyright 2025. All Rights Reserved by MedPath